Family · Pharmaceutical analytical standards
Darifenacin
An antimuscarinic for overactive bladder, approved in 2004 in Europe and the United States: it relaxes the bladder muscle by blocking M3 muscarinic receptors, reducing urgency and frequency of urination. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Of the five types of muscarinic receptor it clearly prefers M3, the one that makes the bladder contract: it binds it about 59 times more strongly than M2, the subtype that dominates in the heart.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
